Dana Farber Cancer Institute/Massachusetts General Hospital — Boston, Massachusetts

Dana Farber Cancer Institute/Massachusetts General Hospital is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 71/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute/Massachusetts General Hospital has participated in 6 clinical trials.

Therapeutic areas: Anemia, Sickle Cell, Acute Leukemia, Myelodysplasia.

Sponsors: Emory University, National Heart, Lung, and Blood Institute (NHLBI), Medical College of Wisconsin.

Sponsor Feasibility Report

Trust Score: 71/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute/Massachusetts General Hospital?

Dana Farber Cancer Institute/Massachusetts General Hospital has a Crixeo Trust Score of 71/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute/Massachusetts General Hospital conducted?

Dana Farber Cancer Institute/Massachusetts General Hospital has 6 clinical trials on record. Their work covers Anemia, Sickle Cell, Acute Leukemia, Myelodysplasia.

Is Dana Farber Cancer Institute/Massachusetts General Hospital accredited by Crixeo Health?

Yes — Dana Farber Cancer Institute/Massachusetts General Hospital holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Dana Farber Cancer Institute/Massachusetts General Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.